Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis.

@article{King2015EvaluationOT,
  title={Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis.},
  author={R. Bruce King and Cynthia W. Tuthill},
  journal={Expert opinion on biological therapy},
  year={2015},
  volume={15 Suppl 1},
  pages={S41-9}
}
OBJECTIVES Recent understanding of the complex pathophysiology of melanoma and severe sepsis suggests that immune-modulating compounds such as thymosin alpha 1 (INN: thymalfasin; abbreviated Ta1) could be useful in the treatment of these two unrelated immune-suppressing indications. RESEARCH DESIGN AND METHODS Three nonclinical murine models were utilized, including: i) a lung metastasis B16 model; ii) a B16-based tumor growth model; and iii) a cecal-ligation and puncture (CLP) sepsis model… CONTINUE READING